Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration‐resistant prostate cancer patients treated with abiraterone. Issue 12 (28th July 2017)

• Record Type: Journal Article
• Authors: Fan, Liancheng; Wang, Xiao; Chi, Chenfei; Wang, Yanqing; Cai, Wen; Shao, Xiaoguang; Xu, Fan; Pan, Jiahua; Zhu, Yinjie; Shangguan, Xun; Xin, Zhixiang; Hu, Jianian; Xie, Shaowei; Wang, Rui; Zhou, Lixin; Dong, Baijun; Xue, Wei
• Is Part Of: Prostate. Volume 77:Issue 12(2017)
• Page Start: 1233
• Page End: 1241
• Publication Date: 2017-07-28
• Subjects: abiraterone acetate -- metastatic castration‐resistant prostate cancer -- prognostic model -- PSA flare; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23381
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract : Objective: To determine if prognostic nutritional index (PNI) and its variation could predict initial response to treatment and prognosis in metastatic castration‐resistant prostate cancer (mCRPC) patients treated with Abiraterone (AA). Patients and Methods: One‐hundred‐twelve chemotherapy pretreated or chemotherapy‐naive patients were scheduled for systemic treatment with AA. PNI levels were measured before and after one month of AA treatment. Univariate and multivariate logistic regression analyses were used to identify predictive factors of initial response to AA treatment. Univariable and Multivariable Cox regression analyses were performed to determine prognostic factors that were associated with PSA progression‐free survival (PSA‐PFS), radiographic PFS (rPFS) and overall survival (OS). The Harrell concordance index with variables only or combined PNI data were used to evaluate the prognostic accuracy. Results: Eighty‐one (72.3%) of 112 patients showed initial response to AA treatment, in which 15 experienced PSA flare during AA treatment. In multivariate logistic regression analyses, high baseline PNI level, PSA level decrease during the first month of AA treatment and PNI level elevation during the first month of AA treatment were significantly correlated with initial response to AA treatment. In multivariate Cox regression analysis, low PNI level remained significant predictors of OS, rPFS and PSA‐PFS. The estimated c‐index of the multivariate model for OS increased from 0.82 without PNI to 0.83 when PNI added. Conclusion: Independent of PSA level variation, PNI level elevation during the first month of AA treatment and high baseline PNI level were significantly correlated with initial response to AA treatment. In addition, low pretreatment PNI level is a negative independent prognosticator of survival outcomes in mCRPC treated with AA and also increases the accuracy of established prognostic model.